Undervalued Small Caps With Insider Buying Opportunities For December 2024

In This Article:

As global markets navigate a period of economic uncertainty, smaller-cap stocks have faced challenges, with the Russell 2000 Index underperforming larger peers like the S&P 500. Amidst expectations for a Federal Reserve rate cut and signs of a cooling labor market, investors are closely watching small-cap opportunities that may offer potential value in this shifting landscape. In such an environment, identifying stocks with strong fundamentals and strategic insider activity can be crucial for those seeking to capitalize on current market dynamics.

Top 10 Undervalued Small Caps With Insider Buying

Name

PE

PS

Discount to Fair Value

Value Rating

Maharashtra Seamless

12.0x

2.1x

24.07%

★★★★★☆

Avia Avian

14.7x

3.4x

20.20%

★★★★★☆

ABG Sundal Collier Holding

12.3x

2.1x

41.03%

★★★★☆☆

Optima Health

NA

1.3x

46.65%

★★★★☆☆

Treatt

19.5x

1.8x

48.53%

★★★☆☆☆

Gooch & Housego

41.2x

1.0x

31.94%

★★★☆☆☆

Hemisphere Energy

6.0x

2.3x

-110.15%

★★★☆☆☆

Community West Bancshares

18.7x

2.9x

42.25%

★★★☆☆☆

Safari Investments RSA

5.0x

2.9x

10.93%

★★★☆☆☆

Digital Mediatama Maxima

NA

1.2x

16.29%

★★★☆☆☆

Click here to see the full list of 185 stocks from our Undervalued Small Caps With Insider Buying screener.

Underneath we present a selection of stocks filtered out by our screen.

Ryman Healthcare

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Ryman Healthcare is a company that specializes in the provision of integrated retirement villages for older people, with a market capitalization of approximately NZ$6.45 billion.

Operations: The company's revenue primarily stems from the provision of integrated retirement villages, with recent figures showing revenue at NZ$720.35 million. Over time, there has been a notable decline in gross profit margin, which decreased to 2.37% as of September 2024. Operating expenses have consistently increased, impacting overall profitability and contributing to net income losses in recent periods.

PE: -33.2x

Ryman Healthcare, a smaller company in the healthcare sector, recently reported half-year revenue of NZ$366.26 million, up from NZ$333.63 million last year, though net income dropped to NZ$94.37 million from NZ$187.08 million previously. Despite this dip in earnings per share and high debt levels reliant on external borrowing, insider confidence was evident with purchases made throughout 2024. Earnings are projected to grow annually by 27%, suggesting potential for future value realization amidst current challenges.